| Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.Lancet Respir Med | PMID 39756424PMC12184100 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211.Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39788823无 PMCID | 2025-Mar | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.Eur J Heart Fail | PMID 39792342PMC11955314 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen-reduced red cells in complex cardiac surgery patients.Transfusion | PMID 39801369无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Frailty on Antihypertensive Treatment in Older Adults.Hypertension | PMID 39807596无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.Leukemia | PMID 39815052无 PMCID | 2025-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial.Lancet Gastroenterol Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39824200无 PMCID | 2025-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis.Eur Urol | PMID 39827019无 PMCID | 2025-Mar | 0.85 | The record describes an interim safety analysis from a phase 3 randomized trial in oncology, but it does not report the required survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes for KM digitization. | 待处理 |
| Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.Nat Med | PMID 39863775PMC11922750 | 2025-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.Lancet Diabetes Endocrinol | PMID 39870096无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of lemborexant on sleep architecture in participants with insomnia disorder and mild obstructive sleep apnea.Sleep Med | PMID 39879708无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis.Circ Heart Fail | PMID 39882614无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Role of Serum Free Fatty Acids in Endothelium-Dependent Microvascular Function.Endocrinol Diabetes Metab | PMID 39888728PMC11784902 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39893774无 PMCID | 2025-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials.Lancet Respir Med | PMID 39900091无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pressure pain threshold and perceived impact of pain differentially predict short-term and long-term pain reduction following acupuncture in fibromyalgia.J Integr Med | PMID 39915157无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial.Lancet Haematol | PMID 39919775无 PMCID | 2025-Mar | 0.85 | This is a randomized phase III trial in hematological malignancies with a primary time-to-event endpoint (disease-free survival). However, the intervention compares different graft sources (haploidentical PBSCs + unrelated cord blood vs. haploidentical PBSCs + bone marrow), which are cellular therapies/transplant procedures, not a drug-containing intervention. The eligibility criteria require a drug-containing intervention, which is not met here. | 待处理 |
| Anesthesia-induced electroencephalogram oscillations and perioperative outcomes in older adults undergoing cardiac surgery.J Clin Anesth | PMID 39921932PMC11953626 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39923717无 PMCID | 2025-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.Adv Ther | PMID 39932677PMC11868361 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial.Lancet Haematol | PMID 39947215无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39952264无 PMCID | 2025-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial.Lancet HIV | PMID 39954697PMC12338333 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials.Mult Scler Relat Disord | PMID 39965438无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 1:非 KM 图;Figure 2:森林图/亚组分析图。 | PMID 39985889PMC11904580 | 2025-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial.EBioMedicine | PMID 40020259PMC11919330 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study.Clin Transl Sci | PMID 40025846PMC11873365 | 2025-Mar | 0.95 | The record describes a Phase III randomized trial with a drug intervention in oncology, but the primary efficacy endpoint is not a time-to-event outcome (e.g., Kaplan-Meier or HR). The main results focus on MRD-negative CR rate and exposure-response analyses for safety and efficacy, which do not meet the required time-to-event efficacy endpoint criterion. | 待处理 |
| Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions.J Neuromuscul Dis | PMID 40033991PMC13142871 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.J Neuromuscul Dis | PMID 40034001PMC13142868 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.ESMO Open | PMID 40056850PMC11930716 | 2025-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia.Ann Hematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图。 | PMID 40063243PMC12031924 | 2025-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial.CNS Drugs | PMID 40111738PMC11950099 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Once-Nightly Sodium Oxybate in Patients with Narcolepsy: Post Hoc Analyses of Sensitivity, Effect Size, and Numbers Needed to Treat from the Phase 3 REST-ON Trial.CNS Drugs | PMID 40111739PMC11950104 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India.JCO Glob Oncol | PMID 40127383无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis.Arq Bras Cardiol | PMID 40243852PMC12107767 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.N Engl J Med | PMID 39651791PMC11864901 | 2025-Feb-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A phase 3 clinical trial on the immunogenicity and safety of booster vaccination after Zagreb or Essen regimens.Sci Rep | PMID 40016280PMC11868620 | 2025-Feb-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial.Sci Rep | PMID 40016311PMC11868424 | 2025-Feb-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial.Stroke Vasc Neurol | PMID 38858097PMC11877429 | 2025-Feb-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.JAMA | PMID 39671272PMC11862970 | 2025-Feb-25 | 0.95 | The study is a randomized Phase III trial in human oncology with a drug intervention and reports original results. However, the primary efficacy endpoint is pathological complete response (pCR), a binary endpoint, not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP. No Kaplan-Meier analysis or hazard ratio for a time-to-event endpoint is mentioned in the abstract. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.Eur J Cancer | PMID 39798264无 PMCID | 2025-Feb-25 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial.J Am Coll Cardiol | PMID 39846936无 PMCID | 2025-Feb-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.Eur J Cancer | PMID 39864363无 PMCID | 2025-Feb-25 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39879779无 PMCID | 2025-Feb-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip.BMC Musculoskelet Disord | PMID 40001000PMC11853225 | 2025-Feb-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial.Clin Infect Dis | PMID 39523543PMC11848284 | 2025-Feb-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial.BMJ | PMID 39993822PMC11848676 | 2025-Feb-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.Lancet | PMID 39919773无 PMCID | 2025-Feb-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intermittent screening using ultra-sensitive malaria rapid diagnostic test and treatment with pyronaridine-artesunate compared to standard preventive treatment with sulfadoxine-pyrimethamine for malaria prevention in pregnant women in Kinshasa, DRC.Malar J | PMID 39985024PMC11846385 | 2025-Feb-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study.Medicine (Baltimore) | PMID 39993074PMC11856878 | 2025-Feb-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |